Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › arbaclofen

arbaclofen

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of arbaclofen

3 trials tracked of arbaclofen: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 2 citations.

3Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 1
  1. Phase 3 A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS Completed · 2 cited
  2. Phase 3 A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS Completed
  3. Phase 2 Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GABA-modulating pharmacotherapies show inconsistent results for improving symptoms in autism spectrum disorder
Neurology Meta-analysis
GABA-modulating pharmacotherapies show inconsistent results for improving symptoms in autism spectrum disorder New data shows mixed results for medications targeting autism symptoms
This meta-analysis evaluated the impact of bumetanide, arbaclofen, and valproate on various symptom domains in individuals with autism spect…
Research into three specific drugs for autism shows some initial signs of improvement, but the evidence is currently too inconsistent to be …
medRxiv Aug 25, 2026
Arbaclofen Phase 3 Trials Establish Clinically Meaningful Change Thresholds in Fragile X Syndrome
Drug Pipeline Phase III
Arbaclofen Phase 3 Trials Establish Clinically Meaningful Change Thresholds in Fragile X Syndrome New Rules for Measuring Behavior Change in Fragile X
A review of two Phase 3 trials in 278 individuals with Fragile X Syndrome (aged 5-50 years) established clinically meaningful change thresho…
Imagine a parent watching their child struggle with daily routines.
Apr 24, 2026